{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-344584","form_type":"8-K","ticker":"ERAS","cik":"0001761918","company_name":"Erasca, Inc.","filed_at":"2026-08-11T20:05:19+00:00","discovered_at":"2026-08-11T20:07:00.452790+00:00","generated_at":"2026-08-11T20:07:59.479159+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Erasca Q2 net loss $44.1M; ERAS-0015 57% uORR in PDAC; raises $632M","bullets":["Q2 2026 net loss $44.1M ($0.14/sh) vs $33.9M ($0.12/sh) in Q2 2025; R&D expense $35.9M vs $21.2M.","Cash $384.3M at June 30, 2026; July upsized offering raised ~$632.5M gross, Jan 2026 offering ~$258.8M.","ERAS-0015 at 32mg QD showed 57% uORR8wk in 2L+ KRAS G12X PDAC; no DLTs, no tx-related discontinuations, 100% median dose intensity.","Plans for three registration-enabling trials: 2L+ NSCLC (H1 2027), 1L PDAC (2027), RASm NSCLC (H2 2027-H1 2028).","Appointed Charles Fuchs as president of R&D and David Chonzi as SVP global pharmacovigilance in August 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-344584","json":"https://secwatch.observer/filing/0001193125-26-344584.json","markdown":"https://secwatch.observer/filing/0001193125-26-344584.md","text":"https://secwatch.observer/filing/0001193125-26-344584.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1761918/000119312526344584/0001193125-26-344584-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1761918/000119312526344584/eras-20260811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-11T20:07:59.479159+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}